Abstract: Female breast cancer is the second in frequency after cervical cancer. Surgery is the most common treatment for breast cancer, followed by chemotherapy as a treatment of choice. Although effective, it causes serious side effects. Controlled-release drug delivery is an alternative method to improve the efficacy and safety of the treatment. It can release the dosage of drug between the minimum effect concentration (MEC) and minimum toxic concentration (MTC) within tumor tissue and reduce the damage of normal tissue and the side effect. Because an in vivo experiment of this system can be time-consuming and labor-intensive, a mathematical model is desired to study the effects of important parameters before the experiments are performed. Here, we describe a 3D mathematical model to predict the release of doxorubicin from pluronic gel to treat human breast cancer. This model can, ultimately, be used to effectively design the in vivo experiments.
Abstract: Acute kidney injury (AKI) is a new worldwide public
health problem. A diagnosis of this disease using creatinine is still a
problem in clinical practice. Therefore, a measurement of biomarkers
responsible for AKI has received much attention in the past couple
years. Cytokine interleukin-18 (IL-18) was reported as one of the
early biomarkers for AKI. The most commonly used method to
detect this biomarker is an immunoassay. This study used a planar
platform to perform an immunoassay using fluorescence for
detection. In this study, anti-IL-18 antibody was immobilized onto a
microscope slide using a covalent binding method. Make-up samples
were diluted at the concentration between 10 to 1000 pg/ml to create
a calibration curve. The precision of the system was determined
using a coefficient of variability (CV), which was found to be less
than 10%. The performance of this immunoassay system was
compared with the measurement from ELISA.